Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Warfarin loading dose guided by pharmacogenetics is effective and safe in cardioembolic stroke patients - a randomized, prospective study

T. Ruzickova, M. Sramek, V. Kaplan, S. Kumstyrova, Z. Lacinova, P. Jansky, H. Magerova, I. Sarbochova, JP. Schwabova, V. Matoska, A. Tomek,

. 2019 ; 19 (5) : 446-454. [pub] 20190116

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025638

Warfarin treatment is commonly started with a fixed loading dose that might be associated with an increased risk of bleeding. An individual maintenance dose can then be estimated based on a pharmacogenetic algorithm. Starting treatment with the estimated dose implies a longer time to reach the therapeutic range. Our goal was to compare the safety and efficacy of initiating warfarin treatment with a loading dose guided by pharmacogenetics versus a maintenance dose. The primary endpoint was time in the therapeutic range (TTR) in the first 10 days of treatment. Secondary endpoints were time to the first international normalized ratio (INR) in therapeutic range (2.0-3.0) and occurrence of serious adverse events. Consenting cardioembolic stroke patients were genotyped for CYP2C9 (cytochrome P450 2C9 gene) and VKORC1 (vitamin K epoxide reductase complex, subunit 1 gene) polymorphisms and a maintenance warfarin dose was estimated. Patients were randomized into two groups. The loading dose group (LDG) patients received twice the estimated dose in the first 2 days of treatment. The maintenance dose group (MDG) patients received the estimated dose directly from day one. The TTR in the first 10 days was significantly higher in the LDG than in the MDG (50.5% vs. 38.3%, p = 0.003). The time to the first INR in this range was significantly shorter in the LDG (5.24 vs. 7.3 days). There were no significant differences in the INR above this range or serious adverse events. Warfarin loading dose guided by pharmacogenetics after recent cardioembolic stroke improved the efficacy of warfarin initiation without increasing the risk of adverse events.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025638
003      
CZ-PrNML
005      
20201222155323.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41397-019-0066-4 $2 doi
035    __
$a (PubMed)30647445
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ruzickova, Tereza $u Department of Neurology, 2nd Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic. terez.ruzickova@gmail.com.
245    10
$a Warfarin loading dose guided by pharmacogenetics is effective and safe in cardioembolic stroke patients - a randomized, prospective study / $c T. Ruzickova, M. Sramek, V. Kaplan, S. Kumstyrova, Z. Lacinova, P. Jansky, H. Magerova, I. Sarbochova, JP. Schwabova, V. Matoska, A. Tomek,
520    9_
$a Warfarin treatment is commonly started with a fixed loading dose that might be associated with an increased risk of bleeding. An individual maintenance dose can then be estimated based on a pharmacogenetic algorithm. Starting treatment with the estimated dose implies a longer time to reach the therapeutic range. Our goal was to compare the safety and efficacy of initiating warfarin treatment with a loading dose guided by pharmacogenetics versus a maintenance dose. The primary endpoint was time in the therapeutic range (TTR) in the first 10 days of treatment. Secondary endpoints were time to the first international normalized ratio (INR) in therapeutic range (2.0-3.0) and occurrence of serious adverse events. Consenting cardioembolic stroke patients were genotyped for CYP2C9 (cytochrome P450 2C9 gene) and VKORC1 (vitamin K epoxide reductase complex, subunit 1 gene) polymorphisms and a maintenance warfarin dose was estimated. Patients were randomized into two groups. The loading dose group (LDG) patients received twice the estimated dose in the first 2 days of treatment. The maintenance dose group (MDG) patients received the estimated dose directly from day one. The TTR in the first 10 days was significantly higher in the LDG than in the MDG (50.5% vs. 38.3%, p = 0.003). The time to the first INR in this range was significantly shorter in the LDG (5.24 vs. 7.3 days). There were no significant differences in the INR above this range or serious adverse events. Warfarin loading dose guided by pharmacogenetics after recent cardioembolic stroke improved the efficacy of warfarin initiation without increasing the risk of adverse events.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antikoagulancia $x aplikace a dávkování $7 D000925
650    _2
$a ischemie mozku $x farmakoterapie $7 D002545
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a INR $7 D019934
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a farmakogenetika $7 D010597
650    _2
$a prospektivní studie $7 D011446
650    _2
$a cévní mozková příhoda $x farmakoterapie $7 D020521
650    _2
$a warfarin $x aplikace a dávkování $x škodlivé účinky $7 D014859
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sramek, Martin $u Department of Neurology, 2nd Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic. Department of Neurology, Central Military University Hospital, Prague, Czech Republic.
700    1_
$a Kaplan, Vojtech $u Hospital Na Homolce, Department of Clinical Biochemistry, Haematology and Immunology, Laboratory of Molecular Genetics, Prague, Czech Republic.
700    1_
$a Kumstyrova, Simona $u Hospital Na Homolce, Department of Clinical Biochemistry, Haematology and Immunology, Laboratory of Molecular Genetics, Prague, Czech Republic.
700    1_
$a Lacinova, Zuzana $u Hospital Na Homolce, Department of Clinical Biochemistry, Haematology and Immunology, Laboratory of Molecular Genetics, Prague, Czech Republic.
700    1_
$a Jansky, Petr $u Department of Neurology, 2nd Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic.
700    1_
$a Magerova, Hana $u Department of Neurology, 2nd Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic.
700    1_
$a Sarbochova, Ivana $u Department of Neurology, 2nd Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic.
700    1_
$a Schwabova, Jaroslava Paulasova $u Department of Neurology, 2nd Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic.
700    1_
$a Matoska, Vaclav $u Hospital Na Homolce, Department of Clinical Biochemistry, Haematology and Immunology, Laboratory of Molecular Genetics, Prague, Czech Republic.
700    1_
$a Tomek, Ales $u Department of Neurology, 2nd Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic. Hospital Na Homolce, Department of Clinical Biochemistry, Haematology and Immunology, Laboratory of Molecular Genetics, Prague, Czech Republic.
773    0_
$w MED00008068 $t The pharmacogenomics journal $x 1473-1150 $g Roč. 19, č. 5 (2019), s. 446-454
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30647445 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155318 $b ABA008
999    __
$a ok $b bmc $g 1599783 $s 1116324
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 19 $c 5 $d 446-454 $e 20190116 $i 1473-1150 $m Pharmacogenomics journal $n Pharmacogenomics J $x MED00008068
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace